Table 1 Model parameters
Parameter | Description | Value | Source |
|---|---|---|---|
Demographic parameters | |||
 Birth rate | Fraction of annual birth cohort out of total French population | 0.01295 | INSEE, www.insee.fr [54] |
Biological parameters | |||
 σ | Latent period of varicella (average duration: 14 days) | 26.07 | Brisson et al. [20] |
 α | Infectious period of varicella (average duration: 7 days) | 52.14 | Brisson et al. [20] |
 δ | Waning natural immunity (average duration: 10 years) | 0.1 | Expert opinion |
 g * λ (a) | Exogenous boosting against zoster |  | Brisson et al. [35] |
 < 50 years | 75% * λ |  | |
 50–64 years | 71%* λ |  | |
 > 65 years | 50%* λ |  | |
Vaccine parameters | |||
 mmr1 | Coverage of first dose of MMR French current coverage | 90% |  |
 mmr2 | Coverage of second dose of MMR French current coverage | 80% |  |
 Dose1 | Age at first vaccination (in months) | 12 | Assumption |
 Dose2 | Age at second vaccination (in months) | 18 | Assumption |
 Introduction time | Number of years before maximum vaccination coverage is reached | 3 | Assumption |
 Tv | Varicella vaccine efficacy (% successfully vaccinated and temporarily protected) | 65% | Prymula et al. [45]; NCT00226499 |
 P | Varicella vaccine failures (%) | 5% | Prymula et al. [45]; NCT00226499 |
 1-Tv-P | Varicella vaccine-recipients partially protected (%) | 30% | 100%-Tv-P |
 Wv1 | Waning rate for 1 dose of varicella vaccine (duration 17 years) | 0.0588 | Silverman et al. [55] |
 Wv2 | Waning rate for 2 doses of varicella vaccine (lifelong protection) | 1e− 6 | Expert opinion |
 Ki * λ (a) | Rate of exogenous boosting | 0.91 * λ (a) | Brisson et al. [20] |
 h | Relative VZV reactivation after varicella vaccination | 0.167 | Brisson et al. [20] |
 b * λ (a) | Rate of infection among vaccinated susceptibles | 0.73 * λ (a) | Brisson et al. [20] |
 m | Relative infectiousness of infected vaccine-recipients versus non-vaccine-recipients | 0.5 | Brisson et al. [20] |